BiVictriX Therapeutics PLCLSE BiVictriX Therapeutics Stock Report

BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm is building a novel pipeline of therapeutics that have cancer selectivity by reducing harmful side-effects. The firm has developed Bi-Cygni therapeutics, which are uniquely selective for cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side effects. Bi-Cygni therapeutics are designed to target antigen co-expression fingerprints, or twin antigens and on tumor cells, which are largely absent from healthy cells. The Company’s Bi-Cygni product candidate, BVX001, which is for the treatment of acute myeloid leukaemia (AML). The firm is also exploring the breadth of its Bi-Cygn approach across a range of various cancer types through its broad pipeline of anti-cancer therapeutic assets, which includes BVX002 and BVX003.